STALICLA appoints Dr. Purnanand Sarma, PhD, as Chair of the Board of Directors
Sarma1 2 Dr. Purnanand Sarma, PhD Press Release Dr. Sarma brings exceptional expertise in all facets of the pharmaceutical and...
Autism
SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company
According to the agreement, SciSparc’s pharmaceuticals assets are valued at approximately $11.6 million TEL AVIV, Israel, July 08, 2024 (GLOBE...
Transforming Children’s Lives: DP World’s Aviv Clinics Dubai’s Revolutionary Youth Protocol
DUBAI, United Arab Emirates, July 07, 2024 (GLOBE NEWSWIRE) -- At DP World's Aviv Clinics Dubai, the world’s most advanced...
STALICLA publishes pioneering phase 1b data on precision treatment for autism spectrum disorder in Biomedicines
Press Release STALICLA’s precision psychiatry study highlights strong EEG-based target engagement of STP1 treatment in defined subgroup of patients with...
Action Behavior Centers Establishes the Action Institute for Outcomes Research Led by Dr. Linda LeBlanc
AUSTIN, TX / ACCESSWIRE / June 21, 2024 / Action Behavior Centers is thrilled to announce the establishment of the...
Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome
CNM-Au8 demonstrated neuroprotective effects in an in vitro model of Rett Syndrome, a rare pediatric neurodevelopmental diseaseCNM-Au8 also demonstrated rescue...
Christopher Barnett, Founder & CEO of ABA Centers, Named Entrepreneur Of The Year 2024 Florida Winner by EY
FORT LAUDERDALE, Fla., June 17, 2024 /PRNewswire/ -- This weekend, Ernst & Young LLP (EY US) named Christopher Barnett, Founder &...
AscellaHealth Chairman and President Bill Oldham Named 2024 Philadelphia Titan 100
BERWYN, Pa.--(BUSINESS WIRE)--Titan CEO and headline sponsor Wipfli LLP are pleased to announce Bill Oldham, chairman and president, AscellaHealth, as a...
Spinogenix Announces U.S. FDA Orphan Drug Designation Granted to SPG601 for the Treatment of Fragile X Syndrome
Receiving Orphan Drug Designation for SPG601 emphasizes the pressing demand for novel therapies for individuals living with Fragile X SyndromeSAN...
Action Behavior Centers and Austin’s JW Marriott Partner Host Community Impact Event With The Make-A-Wish Foundation
AUSTIN, TX / ACCESSWIRE / May 9, 2024 / Action Behavior Centers, a leading provider of applied behavior analysis (ABA)...
Action Behavior Centers and Austin’s JW Marriott Partner Host Community Impact Event With The Make-A-Wish Foundation
AUSTIN, TX / ACCESSWIRE / May 9, 2024 / Action Behavior Centers, a leading provider of applied behavior analysis (ABA)...
NeuroSigma Announces Acceptance into 2024 Cohort of the KidsX Accelerator Program
LOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. today announced its acceptance into the 2024 cohort of the...
PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy
TARRYTOWN, New York, May 07, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (OTC:PXMD), a biopharmaceutical company focused on advancing...
STALICLA initiates U.S. Phase 3 enabling DDI study of STP7 (Mavoglurant) to treat cocaine use disorder
Geneva, Switzerland, May 2, 2024 – STALICLA SA, a late-stage biotechnology company specializing in precision medicine for brain disorders, announces...
PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101
TARRYTOWN, New York, April 23, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica Inc. (Nasdaq: PXMD) (the “Company”), a leading...
PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission
TARRYTOWN, New York, April 11, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on...
Bionano Announces Publication Showing that OGM Identifies Genetic Aberrations in Sarcoma Samples that May Lead to Improved Diagnosis but were Missed by Classical Cytogenetics
SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of a peer-reviewed study...
PharmAla Biotech Signs Sale Agreement with Numinus
LaNeo Product Data submitted for a Clinical Trial in CanadaTORONTO, March 26, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc....
Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome
TNX-2900 is a proprietary magnesium-potentiated formulation of intranasal oxytocin, a naturally occurring hormone that reduces appetite and eating Prader Willi...
Rose Hill Partners with University of Guelph for Groundbreaking Study to Advance Research for the Potential Benefits of Psilocybin Mushrooms to Address Autism in the Adolescent Brain
World’s first legal exporters of psilocybin solidifies partnership with acclaimed university in Canada for preclinical studiesRUNAWAY BAY, Jamaica, March 21,...